5 documents found, page 1 of 1
Posterior talar process as a suitable cell source for treatment of cartilage an...
Correia, Sandra I.; Silva-Correia, Joana; Pereira, H.; Canadas, Raphael Faustino; Morais, Alain; Frias, A. M.; Sousa, R. A.; van Dijk, C.N.Osteochondral defects of the ankle are common lesions affecting the talar cartilage and subchondral bone. Current treatments include cell-based therapies but are frequently associated with donor-site morbidity. Our objective is to characterize the posterior process of the talus (SP) and the os trigonum (OT) tissues and investigate its potential as a new source of viable cells for application in tissue engineeri...
Finely tuned fiber-based porous structures for bone tissue engineering applicat...
Ribeiro, Viviana; Silva-Correia, Joana; Morais, Alain; Correlo, Vitor M.; Marques, Alexandra P.; Ribeiro, Ana; Silva, Carla; Durães, Nelson
Textile-based silk scaffolds for bone tissue engineering applications
Ribeiro, Viviana; Morais, Alain; Correlo, Vitor M.; Marques, Alexandra P.; Ribeiro, Ana; Silva, Carla; Durães, Nuno; Bonifácio, Graça; Sousa, RuiINTRODUCTION: Scaffolds developed for bone tissue engineering (TE) need to facilitate and promote cell adhesion, proliferation and neo-tissue formation. They must possess specific properties to allow the new tissue to integrate with the material, without inducing any inflammatory response. The intra-architectural scaffold geometry, porosity, scaffold material and surface area play important roles in this proces...
A one-step combined therapy for cartilage repair: development and performance a...
Morais, Alain; Correia, C.; Vilela, Carlos; Gertrudes, Ana; Santos, T. C.; Oliveira, Joaquim M.; Mendes, João Espregueira; Sousa, R. A.; Reis, R. L.With a progressively ageing and physically active population, joint ailments appear as responsible for activity limitation in adults 18-65 years of age, resulting in reduced quality of life and high socio-economic burden. Despite intensive efforts on the development of cartilage repair strategies worldwide, no current approach has proven full efficacy. In this work, it is proposed a novel one-step combined ther...
The yeast Saccharomyces cerevisiae is sensitive to colorectal cancer routine tr...
Morais, Alain; Ferreira, Célia; Teixeira, Manuel; Lucas, CândidaCetuximab/Erbitux® (Merk Sereno), a drug used in routine treatment of colorectal cancer and other malignant pathologies, is a monoclonal antibody against the Epidermal Growth Factor Receptor (EGFR). A frequent problem affecting the clinical use of Cetuximab is the lack of effectiveness deriving from frequent mutations in K-ras (1-3). A set of mutations in K-ras gene, KRAS c.35G>A (G12D), KRAS c.38G>A (G13D) in ...